🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
19.74
+0.35 (1.81%)
At close: Nov 18, 2026, 4:00 PM EST
19.75
+0.01 (0.05%)
After-hours: Nov 18, 2026, 7:30 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

PREVAIL’s interim trigger was expected in Q4 2026, with DSMB review extending into at least Q1 2027; a decision to stop would precede final adjudication and unblinding. A German launch began in November 2026, with RUBENS data expected in 2027.

Dennis Ding
Biotech Analyst, Jefferies

Good morning. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, Biotech Analyst here at Jefferies, and I have the wonderful pleasure of having NewAmsterdam Pharma here with us. We have the CSO, John Kastelein, and then CFO, Ian Somaiya. Welcome.

Ian Somaiya
CFO, NewAmsterdam Pharma

Thanks, Dennis.

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

Thanks, Dennis.

Dennis Ding
Biotech Analyst, Jefferies

Looking forward into 2027, I think what's top of mind for nearly every investor is PREVAIL and the interim readout that you guys may be disclosing in Q1. Talking with investors, I feel like there's still a lot of sort of misinformation out there in terms of what have you guys said about the statistical assumptions, even the disclosure strategy. Maybe just level set all of us and just make it clear to people, what exactly is the strategy there and some of the statistical assumptions?

Ian Somaiya
CFO, NewAmsterdam Pharma

Yeah. So, thank you, Dennis, and it's great to see so many friends in the audience, and hopefully virtually as well. Before we get into the details of PREVAIL, I think it's important to sort of set the timelines for 2027. It's going to be an exciting year, and it's already started in the year 2026 with Menarini's announcement yesterday of our formal launch in Germany. So we are a commercial company, and the promise of this therapy, and I think we've all seen this class and the number of setbacks over the decades, we were the first to get this drug to the market and to patients, so that's a very exciting time for us. In terms of the clinical developments in 2027, PREVAIL will be one of the many studies that read out next year.

The next closest one for us is RUBENS, which we expect to complete by the end of this year. This is a study in patients with diabetes and metabolic syndrome without ASCVD. This is a population which is at risk for cardiovascular events, who has elevated LDL, and this is a 20, 30-plus million patient opportunity that we'll have data on moving into the new calendar year. Along with PREVAIL, REMBRANDT, which is the, in essence, the outcome study for our fixed-dose combination, it's an imaging trial, which John, you can go into a lot greater detail than I can. We expect that to also finish by the end of next year. John, maybe you can speak more to PREVAIL.

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

Yes, I think it's important to realize that when Michael and I designed PREVAIL, the outcome trial, we used all of our experience of all the trials that we were on the executive committee for, and there were a few things that we knew at that time were extremely important. The first and foremost was, is that you need a high risk at baseline, and since most of the risk at baseline is driven by LDL cholesterol, you want to have an outcome trial with a high LDL cholesterol. I think Novartis has just seen what happens if you have an LDL of 55 at baseline. I think we were right in designing our trial. We enriched it with high-risk patients, diabetics, high triglycerides, low HDL, obesity, insulin resistance. We made sure that we had a very high-risk trial.

We powered the trial to end, in fact, now with 959 MACE -4 events. Actually, this month, we predicted that the trial would end in November of 2026 with just 959 events. Since then, since we started the trial, and we started the trial, also important to know, at the same time that we started our other phase III trials, which is unique because no other company has ever done that. Most companies do first their pivotal registration trials and then go to their outcome trial. We started all at the same time, and we did that because we wanted the trial to be in the same countries, in the same sites, in the same adjudication committee, and the same Data Safety Monitoring Board. So they would be a mirror image of each other.

In fact, we now know that baseline LDL in PREVAIL, our outcome trial, is 103, the highest of any contemporary trial, which allows us this risk reduction that we are striving for. Since we started PREVAIL, we learned, and not only we, but many cardiologists with us, that we needed a better primary outcome parameter, because we've learned, for example, that CVD death also includes heart failure death, and heart failure is not modified by lipid lowering. We know that now. So we have modified from CVD to CHD death. We've also learned that hemorrhagic stroke is not modified by lipids, so we got rid of hemorrhagic stroke, and we now have ischemic stroke.

But most importantly, we also learned that it is better to have all coronary revascularizations instead of just urgent, because there are no elective revascularizations anymore, not even in the U.S., where in the past, some of this was driven by a wallet more so than by science. Going from urgent to all coronary revascs upped the number of events for 4-point MACE considerably, so that, in fact, we now have way more events than the 959 than we originally planned for. That allows us to do an interim analysis for which we are now statistically better prepared than for the original plan with the old MACE -4. What is going to happen is that the trigger for the interim analysis is happening. He always teaches me, I have to say Q4, I say before Christmas, which is the end of this year, so it will definitely happen.

So that is something that we have always said. Then you have to realize that the moment that the trigger happens as a date, we then have to adjudicate all the events, clean the database, prepare the tables, about 30 tables, and that whole package, which should be as good as something that you can present to the FDA, goes to the Data Safety and Monitoring Board. For that, we will need time, at least until the first quarter of next year. The DSMB will look at those tables, and they have our kind of, how do you say that? Our kind of guidance that if the 4-point MACE hits a p-value of less than 0.01, and in capital letters, the MACE -3 hits a p-value of point, point, we have not revealed that, and the third and, there is no safety issue.

So those three things, if that, then we strongly hope, that is the only thing you can say to the DSMB, otherwise they throw you out of the room, that you will stop the trial. They have immense power because they can actually also ignore that and not stop the trial. But we have made it very clear, we have met them at the American Heart meeting, Michael and I, our CEO, and we have told them that these are the surroundings within we hope that they stop the trial. If they stop the trial, then realize that between that moment in time, and we will release that yes, stop the trial, and the trigger, there will be more events happening. We will have to again adjudicate everything that happened before the date that we hear the yes or no, and formally close the entire trial.

Patients will have to come for their last visit, et cetera, et cetera. Then when that has transpired and we have kind of closed the database and we have a CSR, only then will we be unblinded. Only then we will know the hazard ratio, and we will immediately, of course, make that public. So it is important to understand those timelines so that there are no untoward expectations of something that is going to come earlier or later or whatever. So that is what we are doing. We have, as I said, great confidence in the interim analysis because even if we would have not access to blinded event rates, which we do have, then we can simply take LDL cholesterol, the most evidence-based parameter in biology and medicine, and predict what at that time the surroundings of a MACE hazard ratio and a p-value would be.

Now, of course, we do see blinded event rates, and what we see in the blinded event rates make someone like me and Michael Davidson, who have done this for like three decades, optimistic that we will at that time stop the trial. That is, I think, all I can say about how we are going into 2027 with optimism that the DSMB will stop the trial and that we can then start doing the real work.

Dennis Ding
Biotech Analyst, Jefferies

Got it. That's really helpful. I think what you said was really important was that the interim is better powered than the original statistical protocol, which I believe was 80% power for 20%, and that the interim, I think by our math, it's like 90% for 20% now. That's our math. You don't have to.

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

I won't say anything.

Dennis Ding
Biotech Analyst, Jefferies

But what you said was really, really interesting, which is that the stopping criteria, it's sort of a guidance. It's sort of, you're optimistic, you're hopeful that the DSMB would stop the trial under those three things that you just mentioned. But what are some reasons that the DSMB may not actually stop the trial, even though those three criteria are hit? Is there any kind of precedence for that?

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

There are many precedents. There can be a good reason, and there can be a somewhat less good reason. The good reason might be is that you hit the 4-point MACE, you hit the 3-point MACE, you hit no safety, and then there is a positive trend for all-cause mortality that is simply not statistically significant at that point. The DSMB might say, "Listen, if we go on for another nine months or so till the end of 2027, you might become statistically significant for all-cause mortality." I think for patients and for the company, that is so important that we, although we hit everything that you've said, we're not going to stop the trial. The second thing could be, and that is like out of this world, there have been 12 DSMB meetings until now. There have been no safety issues whatsoever.

We see blinded safety events. We have now safety in 13,500 patients with a median follow-up of over three years. We've never seen any safety issue. Nevertheless, you never know. It's clinical medicine, clinical development. There might be a little safety issue that they think, "Well, if we continue the trial for another nine months, it'll kind of peter out." There have been examples of that with pravastatin, for example. If you remember, there was some inkling that there was a negative side effect, so they opened up all the trials and continued, and in the end, there was absolutely nothing. Now, there are examples, and Amarin is, I think, an important example.

Amarin, in REDUCE-IT, their outcome trial, had an interim analysis, and the DSMB said, "Continue the trial." They continued the trial, and then when they looked back, they saw they hit actually the p-values for the interim. The DSMB did not listen to them. They continued the trial. They did that, on hindsight, because the fish oils were always somewhat of a contested medication, and it was the first true outcome trial that looked to be positive, so they simply wanted very robust p- values and very robust data, and they got their very robust data. There's another thing is that you shouldn't read too much into this continue the trial. In SELECT, there was an interim analysis.

Everybody got depressed and said, "Well, the interim analysis was not stopping the trial, so they'll never get to anything reasonable." In fact, they got to a 20% 4-point MACE benefit. If we stop the trial, the result will always be very clinically relevant and robust. You can read that into a stopping of the trial. But if the trial doesn't stop, you can't read I mean, people will do it, I know that, but you can't read too much into it, because we will still be unblinded, and there are many reasons for simply continuing the trial. Please also realize that the end of this trial will be in 2027. Whatever, it will either end by an interim analysis in 2027, or it will end because we'll get to the one-year extension of the trial that we kind of built in.

That is, I think, what I wanted to say.

Dennis Ding
Biotech Analyst, Jefferies

Yeah, perfect. I think that is super helpful, by the way. I think what you said for your first point was really interesting, right? If there is an all-cause mortality trend, right? I believe in BROADWAY, even at one year, you did see a meaningful trend. I think it was around 17% at one year, right? That was not stat sig, so I think that is really interesting. I do not think there has been a lipid-lowering therapy with an all-cause mortality benefit. Is that fair?

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

Simvastatin. Everybody forgets that the 4S trial presented in Berlin in 1994. I was there personally. Most of you were not born, probably. That trial actually had an all-cause mortality benefit, then all the misery about, I mean, the negative vibe that statins have, people forgot that. So, there was, the statins, the first trial had an all-cause mortality benefit. What is interesting is that in Japan, there are about 15,000 people that have no CETP at all. So, it is the only country where CETP deficiency, complete CETP deficiency, is prevalent in a number of provinces. These people live longer than the average Japanese. So, not having CETP is a longevity signal. So, that coincides very nicely with the BROADWAY data of a 17% lower all-cause mortality. Yeah.

Dennis Ding
Biotech Analyst, Jefferies

Okay. What underpins your confidence that obicetrapib can drive a competitive MACE benefit? I mean, you mentioned some of the trial design elements, but what about LDL? What about ApoB and some of these other parameters?

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

Yeah, I think it is. I follow all the discussions, and when you type in ApoB on ChatGPT and CETP inhibition, you get an answer that every analyst asks me. I think it is much better to just look at the science. We have a CTT meta-regression line between LDL and MACE that has 300,000 patient points. It is the most evidence-based line in medicine per se. No other field in medicine has a line or an equation that consists of 300,000 points. It tells you that if you lower LDL cholesterol by 38.7 mg/dL , you are rewarded by a 22.3% MACE 4 reduction. There is nothing more precise than that you can say. We strongly believe in our LDL lowering, but we also believe in our other assets.

We know, for example, we now know for sure that our protection against type 2 diabetes that we saw in our program, but that all CETP inhibitors saw, is the consequence of the HDL increase. We now know very sure after last week's publication in Cell that our Alzheimer signal in BROADWAY derives from the HDL part of CETP inhibition, and very likely the same is true for the renal function benefit that we saw in BROADWAY. It is very clear that if you want to compare us to a PCSK9, a PCSK9 is a razor, and CETP inhibition is a hammer. PCSK9s are great drugs. They have one single function. They knock out PCSK9, they lower LDL, and upregulate the LDL receptor. Our drug lowers LDL, increases HDL, basically changes the entire lipoprotein metabolism, which has a multitude of effects.

I think the fact that we have a 10 mg tablet that has no side effects, that you can take with food, without food, in the morning, in the evening, with every other drug on the planet, and there are no side effects, will drive especially family physicians to go for this drug instead of anything else after a statin. That is why we have a great conviction in the outcome results, but also in the ultimate use of our drug.

Ian Somaiya
CFO, NewAmsterdam Pharma

Yeah.

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

Sure.

Ian Somaiya
CFO, NewAmsterdam Pharma

Dennis, what I would add is the data coming out of AHA was very exciting and clearly gave us confidence going into PREVAIL. We have shared with you our blinded observations in PREVAIL. At the one-year mark, and John walked through this, the similarities between BROADWAY and PREVAIL, BROADWAY designed to be a mini PREVAIL, were quite informative. They were quite telling. The two lines were on top of each other. Beyond that mark, we have shared updates since then, we are seeing continued reduction in the overall event rates. Not only the overall event rates, the individual event rates as well. There are two reasons for that observation. Our belief was we are seeing a clear drug effect. There was clearly a narrative out there that maybe this is because standard of care has improved.

Coming out of AHA, what was quite clear, based on both ZEUS and HORIZON, event rates haven't changed. The standard of care hasn't evolved to a degree. The event rates in the placebo arm would have been entirely predicted based on the baseline LDL levels. If we now eliminate that as a possibility in PREVAIL, what you're left with is what we believe to be happening in the trial, which is the drug is once again conferring a benefit, and we will have the opportunity to be the 41st trial to demonstrate that if you reduce LDL, that should lead to fewer MACE events.

Dennis Ding
Biotech Analyst, Jefferies

Perfect. You guys often talk about the REVEAL study and to focus on the upper tertile-

Ian Somaiya
CFO, NewAmsterdam Pharma

Yeah

Dennis Ding
Biotech Analyst, Jefferies

-of patients with high LDL as sort of like a good indicator and a good point, one of the points that underpins your confidence in PREVAIL. But right now, I feel like investors are also talking a little bit more around Lilly's ACCELERATE trial, which failed at two years. Maybe, would love to hear your perspectives around that, and how do you reconcile that with PREVAIL?

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

Yeah, let's first go at the Merck trial. Merck, although Merck paid for it, Oxford did it. Oxford, just to put it in perspective, is the best clinical trial group ever on the planet and still are. They had the vision to know that at that time, they did not know whether it was the HDL increase or the LDL decrease that actually conferred the heart disease benefit for CETP inhibitors. They said, "The only way we can actually know both is to do a 30,000-patient trial that will give us so much power that we can basically answer any question." They had 30,000 patients, but also they were in the, I would say, in the throes of, "Let's first lower LDL at baseline," which on hindsight was actually not the greatest idea.

Because they had 30,000 patients, and even if their mean baseline was 61, one-third of the patients were above 70. That is 10,000 patients. So the size of that tertile is just as big as our PREVAIL trial. It is the same number of patients. So what you can do, you can go to that tertile and take the seven or 8,000 patients that came closest to PREVAIL and then see what that drug that was half as efficacious as our drug, because it lowered LDL by 17%, actually in the highest tertile, where baseline LDLs were like 73, 74, actually the MACE reduction was 17%.

So that tells you that a CETP inhibitor that is much weaker, as long as you have adequate baseline LDL, and so the absolute difference is adequate, already gives you a MACE benefit of 17%, which in fact is better than what REPATHA and PRALUENT showed in FOURIER and ODYSSEY OUTCOMES. That trial really helps us because we can model from that upper tertile any kind of benefit that we expect to happen in PREVAIL. ACCELERATE is and will always be a riddle. That drug, evacetrapib, actually, I did the phase II. I was the PI of the phase II, and so we went all the way up together with Stephen Nicholls, all the way up to 500 milligram. Imagine our drug inhibits CETP by 90% at one milligram. We learned that from the Japanese phase I.

Here, we had to go with a drug to 500 milligram, and it only lowered CETP by about 75%. So there is this vast difference between evacetrapib and obicetrapib. But nevertheless, they were not happy with the formulation, and so they reformulated the drug and used a dose and a formulation that was not tested in phase II, and went with 130 milligram dose into phase III. Then they thought they had a 31% LDL lowering, but that was the direct assay, and we now know that you cannot use the direct assay for LDL. Actually, the FDA knew that too, because they forced us to do the gold standard for all our trials, which is ultracentrifugation or beta quant. If they would have done that, they would have seen that their LDL lowering was 16%.

When they stopped the trial after two years, with the majority of patients exposed for a very short period of time, they stopped it at a time when the curves were not even able to dissociate. So that was the first mistake. The second, the Cleveland Clinic, who ran that trial program, presented at the ACC afterwards that the drug, in fact, increased CRP and raised blood pressure. And so Mike Lincoff, who actually, and you can still get to it, that slideshow, showed also that that increase was linked to the events in the treatment arm. But unfortunately, that trial was completely shut down, and no one has ever done any more post-hoc analysis to really understand what happened. And so we can speculate whatever we want, but I think it was quite an inferior drug that had off-target effects.

The trial was not well-designed. In fact, the LDL lowering was much lower than they thought, and they stopped the trial too early. In the end, we will not know, but I do not think that we have to take ACCELERATE into account. I am actually getting really bored talking about it because this was like 15 years ago or so. Anacetrapib is a good example, but ACCELERATE will always be like a question mark. We cannot answer it at this time.

Dennis Ding
Biotech Analyst, Jefferies

Got it. Well, unfortunately, that is all the time that we have. I wish we had another 45 minutes.

Ian Somaiya
CFO, NewAmsterdam Pharma

Dennis, you say that every year. Next time, we just need to plan for that.

Dennis Ding
Biotech Analyst, Jefferies

Yeah, we will just do an hour-long fireside. All right. Well, it is great to see you. Thanks for hanging out with us and have a great conference.

Ian Somaiya
CFO, NewAmsterdam Pharma

Thank you, Dennis.

John Kastelein
Chief Scientific Officer, NewAmsterdam Pharma

Thank you.